[go: up one dir, main page]

CN102755331A - Asiatic acid salt hard capsule and preparation method thereof - Google Patents

Asiatic acid salt hard capsule and preparation method thereof Download PDF

Info

Publication number
CN102755331A
CN102755331A CN2011101130649A CN201110113064A CN102755331A CN 102755331 A CN102755331 A CN 102755331A CN 2011101130649 A CN2011101130649 A CN 2011101130649A CN 201110113064 A CN201110113064 A CN 201110113064A CN 102755331 A CN102755331 A CN 102755331A
Authority
CN
China
Prior art keywords
hard capsule
hydrochlorate
herba centellae
asiatic acid
lubricant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2011101130649A
Other languages
Chinese (zh)
Inventor
刘�英
刘全海
张瑱
虞丽芳
陈志祥
肖璘
蔡立
吴学军
金立玲
邓轶方
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Heilongjiang Hongdoushan Pharmaceutical Co Ltd
Shanghai Institute of Pharmaceutical Industry
Original Assignee
Heilongjiang Hongdoushan Pharmaceutical Co Ltd
Shanghai Institute of Pharmaceutical Industry
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Heilongjiang Hongdoushan Pharmaceutical Co Ltd, Shanghai Institute of Pharmaceutical Industry filed Critical Heilongjiang Hongdoushan Pharmaceutical Co Ltd
Priority to CN2011101130649A priority Critical patent/CN102755331A/en
Publication of CN102755331A publication Critical patent/CN102755331A/en
Pending legal-status Critical Current

Links

Landscapes

  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)

Abstract

The invention discloses an asiatic acid salt hard capsule and a preparation method thereof. An asiatic acid salt hard capsule formula comprises 5-40 percent of an asiatic acid amino butantriol salt, 50-95 percent of a filling agent, 0-10 percent of a lubricating agent and 0-2.0 percent of an adhesive, wherein the percentage refers to the mass percentage of each component in the total amount of asiatic acid salt hard capsule contents. The method comprises the following steps of: uniformly mixing the raw materials according to a formula; and filling into the conventional hard capsule shell. The asiatic acid salt hard capsule disclosed by the invention has high bioavailability.

Description

Herba Centellae hydrochlorate hard capsule and preparation method thereof
Technical field
The present invention relates to a kind of Herba Centellae hydrochlorate hard capsule and preparation method thereof.
Background technology
Report asiatic acid and salt thereof can be prevented and treated the fibrotic disease of some internal organs in the prior art, and still, the drug effect of relevant hard capsule is unsatisfactory, and bioavailability is extremely low, effectively utilizes this medicine for maximizing, and this present situation needs to be resolved hurrily.
Summary of the invention
Technical problem to be solved by this invention is that to have overcome the drug effect of existing asiatic acid and salt hard capsule thereof unsatisfactory, and the extremely low defective of bioavailability, and a kind of Herba Centellae hydrochlorate hard capsule with good biological availability and preparation method thereof is provided.
Herba Centellae hydrochlorate hard capsule prescription of the present invention contains 5%~40% asiatic acid tromethane salt, 50%~95% filler, 0%~10% lubricant and 0%~2.0% binding agent, and percentage ratio accounts for the mass percent of Herba Centellae hydrochlorate hard capsule content total amount for each composition.
Among the present invention, described asiatic acid tromethane salt is the conventional described asiatic acid tromethane salt in this area, commercially available get or extract by the asiatic acid raw material according to this area conventional method obtain.
Among the present invention; Described filler is the conventional described filler in this area; Can use diluent for water-soluble diluent, water-insoluble diluent or direct compression; Preferable in trihydroxy aminomethane, sorbitol, sorbitol instant, D-xylose, xylitol, propylene carbonate, calcium glycerophosphate, mannitol, the corn starch of can sterilizing, compressible sugar, polyvinylpolypyrrolidone, inositol, Thomas balsam, maltose alcohol, soda-lime, alpha-lactose, lactose, aluminium hydroxide, medicinal sugar, calcium oxide, zinc oxide, prepared teobroma, pregelatinized Starch, Powderd cellulose, colloidality silicon dioxide, aluminium silicate, Aluminum calcium silicate., starch, sodium chloride, calcium chloride, aluminum chloride, calcium sulfate, glucose, Pulvis Talci, microcrystalline Cellulose, bagasse regrowth, carboxymethylcellulose calcium, polyethylene, polyethylene azoxy ketone, polyvinyl butyral resin, polyethylene acetal diethyl acetate ester, calcium carbonate, magnesium carbonate, magnesium oxide, sucrose, spherical sucrose, compressible sugar, sugar,confectioner's, dextrin, white dextrin, calcium phosphate and the sodium starch phosphate one or more, one or more that better is in microcrystalline Cellulose, lactose and the trihydroxy aminomethane.
Among the present invention; Described lubricant is the conventional described lubricant in this area; Be generally kollag; In preferable is hard paraffin, Palmic acid, synthetic wax, zinc oleate, lithium stearate, potassium stearate, calcium stearate, boric acid, calcium silicates, aluminium silicate, Aluminum calcium silicate., magnesium silicate, silicone rubber, liquid paraffin, hard esteramides, stearic palmitamide, stearic acid, isostearic acid, sodium stearate, hard soap, curdled milk soap, sodium stearate, cobaltous octadecanate, zinc stearate, magnesium stearate, Pulvis Talci, sodium palmitate, Oleum Ricini, SHCO, Polyethylene Glycol, sucrose fatty acid ester, sucrose monolaurate, sucrose palmitic acid ester, olive oil and the calcium phosphate one or more, better is magnesium stearate and/or aluminium silicate.
Among the present invention; Described binding agent is the conventional described binding agent in this area, preferable is ethylmethylcellulose, ethyl cellulose, ethyl cellulose aqueous suspension, butadiene-styrene rubber, natural rubber, acrylic acid, butylacrylate, acrylic acid methyl ester., acrylic resin I number, acrylic resin II number, acrylic resin III number, acrylic resin IV number, Eudragit E 30, chitin, chitose, methyl methacrylate, EMA, butyl methacrylate, EUDRAGIT S100, Eudragit E, acrylic resin L, acrylic resin S, acrylic resin RL, acrylic resin RS, metering system-2-ethoxy, methacrylic acid-2-hydroxypropyl acrylate, methylcellulose, glycerol three rosin esters, zein, compressible sugar, sesbania gum, tara gum, Ficus elastica, carbomer, Petropols, Furcellaran, tragacanth, arabic gum, Resina persicae, maltose alcohol, carrageenin, tamarind gum, high fructose syrup, Nulomoline, fructose, Colophonium, loose glue, POLY-karaya, modified starch, poloxamer, medicinal sugar, alginic acid, sodium alginate, potassium alginate, ammonium alginate, calcium alginate, pregelatinized Starch, Powderd cellulose, hydroxyethylmethyl-cellulose, hydroxyethyl-cellulose, hydroxypropyl methylcellulose, hydroxypropyl cellulose, xanthan gum, aluminium-magnesium silicate, terpene resin, liquid glucose, starch, sodium starch glycol, potassium metaphosphate, scleroglucan, glucose, glucosan, Pullulan, acetyl group Pullulan, microbial alginate, microcrystalline Cellulose, bagasse regrowth, sodium carboxymethyl cellulose, carboxymethylcellulose calcium, Mel, guaiac gum, polyethylene, polyethylene azoxy ketone, polyvinyl butyral resin, polyethylene acetal diethyl acetate ester, polybutene, polybutadiene, polymethyl methacrylate, gather methyl 2-methylmethacrylate copolymer, gather methyl and gather L-methyl methacrylate, sodium polyacrylate, polyacrylic acid, polyisobutylene, Parleam, polystyrene-maleic anhydride, polyvinyl-maleic anhydride, gather in 2-ethoxy formyl acrylic ester, polyvidone, polyvinyl acetate, sucrose, spherical sucrose, compressible sugar, sugar,confectioner's, sucrose fatty acid ester, sucrose monolaurate, sucrose palmitic acid ester, locust bean gum, dextrin, white dextrin, cellulose acetate, a cellulose acetate, cellulose diacetate, Triafol T, cellulose acetate dibutylamino-hydrox-ypropyl ether and the sodium starch phosphate one or more, better is ethyl cellulose.
Preferable being made up of 5%~40% asiatic acid tromethane salt, 50%~95% filler, 0%~10% lubricant and 0%~2.0% binding agent of Herba Centellae hydrochlorate hard capsule prescription of the present invention, percentage ratio accounts for the mass percent of Herba Centellae hydrochlorate hard capsule content total amount for each composition.
The invention still further relates to the Herba Centellae hydrochlorate hard capsule preferred embodiments of filling a prescription and contain 15%~30% asiatic acid tromethane salt, 65%~85% filler, 2%~5% lubricant and 0%~2.0% binding agent, percentage ratio accounts for the mass percent of Herba Centellae hydrochlorate hard capsule content total amount for each composition.
The invention still further relates to the Herba Centellae hydrochlorate hard capsule another preferred embodiments of filling a prescription and be made up of 15%~30% asiatic acid tromethane salt, 65%~85% filler, 2%~5% lubricant and 0%~2.0% binding agent, percentage ratio accounts for the mass percent of Herba Centellae hydrochlorate hard capsule content total amount for each composition.
The invention still further relates to another preferred embodiments of Herba Centellae hydrochlorate hard capsule prescription and contain 16.64%~37.88% asiatic acid tromethane salt, 60.61%~83.19% filler, 0.12%~1.52% lubricant and 0~4.76% binding agent, percentage ratio accounts for the mass percent of Herba Centellae hydrochlorate hard capsule content total amount for each composition.
Wherein, the kind of described filler, lubricant and binding agent all as previously mentioned.
The invention still further relates to Herba Centellae hydrochlorate hard capsule prescription again a preferred embodiments comprise 16.7% asiatic acid tromethane salt, 81.3% lactose and 2% magnesium stearate, percentage ratio accounts for the mass percent of Herba Centellae hydrochlorate hard capsule content total amount for each composition.
Herba Centellae hydrochlorate hard capsule of the present invention can also contain conventional various other additives that add in this area and other active component, as long as it does not have antagonism or not appreciable impact hard capsule effect of the present invention.
Among the present invention; The capsule shells of described Herba Centellae hydrochlorate hard capsule is the conventional hard capsule case that uses in this area; The gel and the water that generally contain conventional usefulness, and one or more compositions of following substances: plasticizer, thickening agent, opacifier, coloring agent, antiseptic and cosolvent etc.
Wherein, Described gel is that this area routine is used, one or more that preferable is in formalin, glycerol, arabic gum, gelatin, POLY-karaya, alginic acid, sodium alginate, calcium alginate, calcium chloride, Pullulan, acetyl group Pullulan, microbial alginate and the Polyethylene Glycol.
Wherein, described capsule shells generally can be made by following method: under vacuum condition, agitating heating becomes glue with capsule shells raw material uniform mixing, and system capsule mechanism capsule gets final product.
Herba Centellae hydrochlorate hard capsule of the present invention can make by this area conventional method, and preferable method for preparing comprises the steps: that by prescription behind each raw material uniform mixing, the conventional hard capsule case in this area of packing into gets final product.
Wherein, described raw material incapsulates the component of shell by the capsule shells volumeter, and capacity such as 0.15mL, 0.25mL, 0.30mL, 0.40mL, 0.55mL and 0.75mL are generally arranged.
Agents useful for same of the present invention and raw material are all commercially available to be got.
On the basis that meets this area general knowledge, each above-mentioned among the present invention technical characterictic optimum condition can combination in any obtain preferred embodiments.
Positive progressive effect of the present invention is: Herba Centellae hydrochlorate hard capsule of the present invention has the good biological availability, and quality stability is good, is difficult for crisp broken; The disintegrate index is stable; Facile hydrolysis not, long-time placement surface is not sent out the mist jaundice, and extensive market prospects and practical value are arranged.
The specific embodiment
Mode through embodiment further specifies the present invention below, but does not therefore limit the present invention among the described scope of embodiments.
Embodiment 1
Figure BSA00000487437800051
Method for preparing: by last table prescription,, be filled in the capsule shells and get final product with medicine and each raw material blending of adjuvant.
Through detecting (rat tail vein injection, visible " Nanfang Medical Univ's journal " 06 phase in 2009), the bioavailability of gained hard capsule asiatic acid tromethane salt is 22.6%.
Embodiment 2
Figure BSA00000487437800052
Method for preparing: by last table prescription,, after the granulation, be filled in the capsule shells and get final product with medicine and each raw material blending of adjuvant.
Embodiment 3
Figure BSA00000487437800053
Method for preparing: by last table prescription,, be filled in the capsule shells and get final product with medicine and each raw material blending of adjuvant.
Effect embodiment
Measure according to 2010 editions correlation methods of Chinese Pharmacopoeia, the result is following:
The effect measuring of the hard capsule of table 1 embodiment 1~3
Embodiment Dissolution (%) The granule color and luster is even Disintegration
1 90.3 Satisfied 7’26”
2 79.7 Better 15’19”
3 69.9 Generally 30’12”
Can know that by last table hard capsule dissolution of the present invention is good, and content granule color and luster is even, good fluidity, and disintegration is shorter.
Comparative Examples 1
Figure BSA00000487437800061
Method for preparing: by last table prescription,, be filled in the capsule shells and get final product with medicine and each raw material blending of adjuvant.
Through detecting (rat tail vein injection, visible " Nanfang Medical Univ's journal " 06 phase in 2009), the bioavailability of asiatic acid potassium salt is 16.8% in the gained hard capsule.
Comparative Examples 2
Figure BSA00000487437800062
Method for preparing: by last table prescription,, be filled in the capsule shells and get final product with medicine and each raw material blending of adjuvant.
Through detecting (rat tail vein injection, visible " Nanfang Medical Univ's journal " 06 phase in 2009), the bioavailability of asiatic acid arginine salt is 1.1% in the gained hard capsule.

Claims (8)

1. Herba Centellae hydrochlorate hard capsule; Its prescription contains 5%~40% asiatic acid tromethane salt, 50%~95% filler, 0%~10% lubricant and 0%~2.0% binding agent, and percentage ratio accounts for the mass percent of Herba Centellae hydrochlorate hard capsule content total amount for each composition.
2. Herba Centellae hydrochlorate hard capsule as claimed in claim 1; It is characterized in that: described Herba Centellae hydrochlorate hard capsule prescription is made up of 5%~40% asiatic acid tromethane salt, 50%~95% filler, 0%~10% lubricant and 0%~2.0% binding agent, and percentage ratio accounts for the mass percent of Herba Centellae hydrochlorate hard capsule content total amount for each composition.
3. Herba Centellae hydrochlorate hard capsule as claimed in claim 1; It is characterized in that: described Herba Centellae hydrochlorate hard capsule prescription contains 15%~30% asiatic acid tromethane salt, 65%~85% filler, 2%~5% lubricant and 0%~2.0% binding agent, and percentage ratio accounts for the mass percent of Herba Centellae hydrochlorate hard capsule content total amount for each composition.
4. Herba Centellae hydrochlorate hard capsule as claimed in claim 3; It is characterized in that: described Herba Centellae hydrochlorate hard capsule prescription is made up of 15%~30% asiatic acid tromethane salt, 65%~85% filler, 2%~5% lubricant and 0%~2.0% binding agent, and percentage ratio accounts for the mass percent of Herba Centellae hydrochlorate hard capsule content total amount for each composition.
5. Herba Centellae hydrochlorate hard capsule as claimed in claim 1; It is characterized in that: described Herba Centellae hydrochlorate hard capsule prescription contains 16.64%~37.88% asiatic acid tromethane salt, 60.61%~83.19% filler, 0.12%~1.52% lubricant and 0~4.76% binding agent, and percentage ratio accounts for the mass percent of Herba Centellae hydrochlorate hard capsule content total amount for each composition.
6. like each described Herba Centellae hydrochlorate hard capsule of claim 1~5, it is characterized in that: described filler is one or more in microcrystalline Cellulose, lactose and the trihydroxy aminomethane; And/or described lubricant is magnesium stearate and/or aluminium silicate; And/or described binding agent is an ethyl cellulose.
7. Herba Centellae hydrochlorate hard capsule as claimed in claim 1; It is characterized in that: described Herba Centellae hydrochlorate hard capsule prescription comprises 16.7% asiatic acid tromethane salt, 81.3% lactose and 2% magnesium stearate, and percentage ratio accounts for the mass percent of Herba Centellae hydrochlorate hard capsule content total amount for each composition.
8. like the method for preparing of each described Herba Centellae hydrochlorate hard capsule of claim 1~7, it comprises the steps: that by described prescription behind each raw material uniform mixing, the conventional hard capsule case in this area of packing into gets final product.
CN2011101130649A 2011-04-29 2011-04-29 Asiatic acid salt hard capsule and preparation method thereof Pending CN102755331A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN2011101130649A CN102755331A (en) 2011-04-29 2011-04-29 Asiatic acid salt hard capsule and preparation method thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2011101130649A CN102755331A (en) 2011-04-29 2011-04-29 Asiatic acid salt hard capsule and preparation method thereof

Publications (1)

Publication Number Publication Date
CN102755331A true CN102755331A (en) 2012-10-31

Family

ID=47050148

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2011101130649A Pending CN102755331A (en) 2011-04-29 2011-04-29 Asiatic acid salt hard capsule and preparation method thereof

Country Status (1)

Country Link
CN (1) CN102755331A (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101969942A (en) * 2008-01-11 2011-02-09 上海医药工业研究院 Therapeutic formulations based on asiatic acid and selected salts thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101969942A (en) * 2008-01-11 2011-02-09 上海医药工业研究院 Therapeutic formulations based on asiatic acid and selected salts thereof

Similar Documents

Publication Publication Date Title
US11878079B2 (en) Pullulan capsules
TWI486178B (en) Nanoparticle suspension containing carboxyvinyl polymer
EP2266582B1 (en) Pharmaceutical composition for preventing dysbiosis associated with enteral administration of antibiotics
CN1927167A (en) Clopidogrel slow, controlled release formulation
CA2710862A1 (en) Pharmaceutical composition for treating diabetes and preparation method thereof
CN103768063B (en) A kind of moxifloxacin hydrochloride medicinal composition and preparation method thereof
CN101433546A (en) Capecitabine sustained and controlled release oral formulation and preparation method thereof
RU2012133568A (en) WAYS AND COMPOSITIONS FOR APPLICATION OF MOXIFLOXACIN IN EAR
CN102614109A (en) Active substance-contained gel composite based on multilayer liquid crystal framework and method for producing same
CN102755331A (en) Asiatic acid salt hard capsule and preparation method thereof
CN103505435A (en) 1-[4-[3-amino-4-hydroxy-3-(hydroxymethyl)butyl]phenyl]-1-acetoxime hydrochloride hard capsule and preparation method thereof
CN102488663B (en) Drug combination containing ethylenediamine diaceturate and preparing method thereof
CN101716153A (en) Ornidazole ester microsphere solid preparation
CN102755332A (en) Asiatic acid salt tablet and preparation method thereof
CN103945832B (en) For brain kinetomeres sustained release and the compositionss of sustained release, device and method
CN101019841A (en) Prepn process and application in medicine for treating liver fibrosis of curcumin
CN1626076B (en) Andrographolide drop pills and preparation method
CN102755330A (en) Asiatate granules and preparation method thereof
CN103479585A (en) 1-[4-[3-amino-4-hydroxy-3-(hydroxymethyl)butyl]phenyl]-1-acetoxime hydrochloride tablet and preparation method thereof
CN103479581A (en) 1-[4-[3-amino-4-hydroxy-3-(hydroxymethyl)butyl]phenyl]-1-acetoxime hydrochloride granules and preparation method thereof
CN103301089B (en) Famciclovir capsule preparation and preparation method thereof
CN102100679A (en) Carprofen matrix tablets
CN101559052A (en) Oral pharmaceutical composition containing mitiglinide and voglibose
CN104116720A (en) Cetirizine hydrochloride soft capsule and preparation method thereof
CN102100683B (en) Slow-soluble external contraceptive membrane

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20121031